Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Sarcoma 1Neuroblastoma 1Multiple Myeloma 1Lymphoma 1Leukemia 1Central Nervous System Neoplasms 1Cardiotoxicity 1Breast Neoplasms 1

Interventions

Cyclophosphamide 34Etoposide 25Doxorubicin 20Carboplatin 20Vincristine 19Isotretinoin 19Topotecan 17Temozolomide 17Irinotecan 16Filgrastim 16Melphalan 15Cisplatin 15sargramostim 14Radiotherapy 14Granulocyte-Macrophage Colony-Stimulating Factor 133-Iodobenzylguanidine 12dinutuximab 11Peripheral Blood Stem Cell Transplantation 11naxitamab 9Thiotepa 9Magnetic Resonance Spectroscopy 9humanized 3F8 anti-GD2 monoclonal antibody 7Granulocyte Colony-Stimulating Factor 7Busulfan 7X-Rays 6Specimen Handling 6Phantoms, Imaging 6Ifosfamide 6Antilymphocyte Serum 6fludarabine phosphate 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neuroblastoma × Fenofibrate × Clear all
NCT00357500 2014-10-01

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
101 enrolled 10 charts
CNSLymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡